Safety
What's worth tracking on therapy, what FDA adverse event reports do and don't tell you, and why the 'research peptide' market is a meaningfully different risk profile from prescription GLP-1s.
11 articles
Safety
GLP-1 medications linked to reduced physical activity in first large wearable study
A large wearable study at ENDO 2026 found GLP-1 users took fewer daily steps and exercised less after starting treatment. Here’s what the data shows — and why it matters.
4 min · Updated 2026-07-06
Safety
GLP-1 medications and bone density: what a new study found — and what it doesn't prove
A 2026 Weill Cornell study found greater hip bone loss in people without diabetes who use semaglutide or tirzepatide. Here's what the data actually shows — and what one retrospective study can't establish.
5 min · Updated 2026-07-06
Safety
What to check before injecting a compounded GLP-1: the FDA's fraud red flags
The FDA has confirmed fraudulent compounded semaglutide and tirzepatide with false pharmacy labels. Here are the specific red flags to check — and how to verify your pharmacy before your next dose.
6 min · Updated 2026-07-06
Safety
Muscle loss on GLP-1s: what the EMBRAZE trial found
In the EMBRAZE Phase 2 trial, apitegromab preserved 54.9% more lean mass than placebo in tirzepatide users without reducing total weight loss. Here's what this means — and what it doesn't.
5 min · Updated 2026-07-06
Safety
What regulators say about unregulated peptides: a consumer protection guide
Health Canada warned consumers about serious risks of injectable peptides bought online. Here's what regulators say — and what the evidence actually supports.
5 min · Updated 2026-06-10
Safety
The research peptide evidence gap: what we actually know about BPC-157 and similar compounds
BPC-157 has plausible biology and thousands of social media claims. But 35 of 36 eligible studies in one systematic review were in rodents. Here's where the evidence actually stands.
7 min · Updated 2026-05-28
Safety
GLP-1 side effects: what to track
A practical list of side effects commonly reported with GLP-1 therapy, what they often mean, and what to log so your clinician can act on patterns.
11 min · Updated 2026-05-27
Safety
Unregulated peptides and real harm: what Australia's hospitalization surge shows
Australia's drug regulator issued a formal safety alert in April 2026 after hospitalizations from unregulated injectable peptides. Here's what consumers should understand.
5 min · Updated 2026-05-27
Safety
What FDA's adverse event reports on compounded GLP-1s actually tell patients
The FDA reports 605 adverse events tied to compounded semaglutide. Here's what those numbers mean — and which risks patients should actually watch for.
6 min · Updated 2026-05-27
Safety
GLP-1 drugs and muscle: what does the science actually say?
A 2026 Cell Reports Medicine study found GLP-1 medicines mainly reduce fat, not muscle. Here's what the latest science shows — and what you and your clinician can do about it.
4 min · Updated 2026-05-27
Safety
'Research peptide' vs prescription GLP-1: why the distinction matters
Vials sold online as 'research only' are not the same product as an FDA-approved or pharmacy-compounded GLP-1. Here is why that gap matters.
6 min · Updated 2026-05-27